merestinib Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Merestinib (LY2801653) is an experimental cancer drug in development by Eli Lilly. It is a small molecule inhibitor of MET and several other receptor tyrosine kinases such as MST1R, FLT3, AXL, MERTK, TEK, ROS1, NTRK1/2/3, and DDR1/2.   Wikipedia

Chemistry

  • SMILES: CC1=CC=C(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3c5cn[nH]c5)c(F)c2)C(=O)N1c6ccc(F)cc6
  • InChIKey: QHADVLVFMKEIIP-UHFFFAOYSA-N
  • Mol. Mass: 552.54
  • ALogP: 5.75
  • ChEMBL Molecule:
    merestinib  
More Chemistry

Pharmacology

Alternative names

ly2801653 | ly-2801653 | merestinib | n-(3-fluoro-4-((1-methyl-6-(1h-pyrazol-4-yl)-1h-indazol-5 yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (14)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (14)


 

Biliary Tract Neoplasms (Phase 2)

Breast Neoplasms (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Cholangiocarcinoma (Phase 1)

Colorectal Neoplasms (Phase 1)

Healthy Volunteers (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Lymphoma, Mantle-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Melanoma (Phase 1)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 1)

Urinary Bladder Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue